Andrei Bieger

Andrei Bieger

Auto-generated profile, based on publicly available information

Andrei Bieger

Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Movement Disorders
Verified
Journal Article
Open access
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
ABAndrei Bieger
Andrei Bieger
OOOlaitan Okunoye
Olaitan Okunoye
KMKin Ying Mok
Kin Ying Mok
SLShen‐Yang Lim
Shen‐Yang Lim
G(Global Parkinson's Genetics Program (GP2)
Global Parkinson's Genetics Program (GP2)
Background: Human genetics research lacks diversity; over 80% of genome‐wide association studies have been conducted on individuals of European ancestry. In addition to limiting insights regarding disease mechanisms, disproportionate representation can create disparities preventing equitable implementation of personalized medicine.Objective: This systematic review provides an overview of research involving Parkinson's disease (PD) genetics in underrepresented populations (URP) and sets a baseline to measure the future impact of current efforts in those populations.Methods: We searched PubMed and EMBASE until October 2021 using search strings for “PD,” “genetics,” the main “URP,” and and the countries in Latin America, Caribbean, Africa, Asia, and Oceania (excluding Australia and New Zealand). Inclusion criteria were original studies, written in English, reporting genetic results on PD from non‐European populations. Two levels of independent reviewers identified and extracted information.Results: We observed imbalances in PD genetic studies among URPs. Asian participants from Greater China were described in the majority of the articles published (57%), but other populations were less well studied; for example, Blacks were represented in just 4.0% of the publications. Also, although idiopathic PD was more studied than monogenic forms of the disease, most studies analyzed a limited number of genetic variants. We identified just nine studies using a genome‐wide approach published up to 2021, including URPs.Conclusion: This review provides insight into the significant lack of population diversity in PD research highlighting the immediate need for better representation. The Global Parkinson's Genetics Program (GP2) and similar initiatives aim to impact research in URPs, and the early metrics presented here can be used to measure progress in the field of PD genetics in the future. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

10 September 2024 in Neurology
Verified
Journal Article
Closed access
ABAndrei Bieger
Andrei Bieger
WBWagner S. Brum
Wagner S. Brum
WBWyllians V. Borelli
Wyllians V. Borelli
JTJoseph Therriault
Joseph Therriault
MBMarco A. De Bastiani
Marco A. De Bastiani
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Updates in Alzheimer disease (AD) diagnostic guidelines by the National Institute on Aging-Alzheimer's Association (NIA-AA) and the International Working Group (IWG) over the past 11 years may affect clinical diagnoses. We assessed how these guidelines affect clinical AD diagnosis in a cohort of cognitively unimpaired (CU) and cognitively impaired (CI) individuals. We applied clinical and biomarker data in algorithms to classify individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort according to the following diagnostic guidelines for AD: 2011 NIA-AA, 2016 IWG-2, 2018 NIA-AA, and 2021 IWG-3, assigning the following generic diagnostic labels: (1) not AD (nAD), (2) increased risk of developing AD (irAD), and (3) AD. Diagnostic labels were compared according to their frequency, convergence across guidelines, biomarker profiles, and prognostic value. We also evaluated the diagnostic discordance among the criteria. A total of 1,195 individuals (mean age 73.2 ± 7.2 years, mean education 16.1 ± 2.7, 44.0% female) presented different repartitions of diagnostic labels according to the 2011 NIA-AA (nAD = 37.8%, irAD = 23.0%, AD = 39.2%), 2016 IWG-2 (nAD = 37.7%, irAD = 28.7%, AD = 33.6%), 2018 NIA-AA (nAD = 40.7%, irAD = 9.3%, AD = 50.0%), and 2021 IWG-3 (nAD = 51.2%, irAD = 8.4%, AD = 48.3%) frameworks. Discordant diagnoses across all guidelines were found in 512 participants (42.8%) (138 [91.4%] occurring in only β-amyloid [CU 65.4%, CI 34.6%] and 191 [78.6%] in only tau-positive [CU 71.7%, CI 28.3%] individuals). Differences in predicting cognitive impairment between nAD and irAD groups were observed with the 2011 NIA-AA (hazard ratio [HR] 2.21, 95% CI 1.34-3.65, p = 0.002), 2016 IWG-2 (HR 2.81, 95% CI 1.59-4.96, p < 0.000), and 2021 IWG-3 (HR 3.61, 95% CI 2.09-6.23, p < 0.000), but not with 2018 NIA-AA (HR 1.69, 95% CI 0.87-3.28, p = 0.115). Over 42% of the studied population presented discordant diagnoses when using the different examined AD criteria, mostly in individuals with a single positive biomarker. Except for 2018 NIA-AA, all guidelines identified asymptomatic individuals at risk of cognitive impairment. Our findings highlight important differences between the guidelines, emphasizing the necessity for updated criteria with enhanced staging metrics, considering clinical, research, therapeutic, and trial design aspects.

8 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
ABAndrei Bieger
Andrei Bieger
OOOlaitan Okunoye
Olaitan Okunoye
KMKin Mok
Kin Mok
SLShen-Yang Lim
Shen-Yang Lim
O(On behalf of the Global Parkinson’s Genetics Program (GP2)
On behalf of the Global Parkinson’s Genetics Program (GP2)
Human genetics research lacks diversity; over 80% of genome-wide association studies (GWAS) have been conducted on individuals of European ancestry. In addition to limiting insights regarding disease mechanisms, disproportionate representation can create disparities preventing equitable implementation of personalized medicine. This systematic review provides an overview of research involving Parkinson’s disease (PD) genetics in under-represented populations (URP), and sets a baseline to measure the future impact of current efforts in those populations. We searched PubMed and EMBASE until October 2021 using search strings for “PD”, “genetics”, the main “URP”, and “lower-to-upper-middle-income countries”. Inclusion criteria were original studies, written in English, reporting genetic results on PD patients from non-European populations. Two levels of independent reviewers identified and extracted relevant information. We observed considerable imbalances in PD genetic studies among URP. Asian participants from China were described in the majority of the articles published (61%), but other populations were less well studied, for example, Blacks were represented in just 4.0% of the publications. Also, although idiopathic PD was more studied than monogenic forms of the disease, most studies analyzed a limited number of genetic variants. We identified just seven studies using a genome-wide approach published up to 2021 including URP. This review provides insight into the significant lack of population diversity in PD research highlighting the urgent need for better representation. The Global Parkinson’s Genetics Program (GP2) and similar initiatives aim to impact research in URP, and the early metrics presented here can be used to measure progress in the field of PD genetics in the future.

24 March 2026 in Neurology
Verified
Journal Article
Closed access
ABAndrei Bieger
Andrei Bieger
WBWagner S. Brum
Wagner S. Brum
WBWyllians Vendramini Borelli
Wyllians Vendramini Borelli
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
JDJaderson Costa DaCosta
Jaderson Costa DaCosta
EZEduardo Zimmer
Eduardo Zimmer

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
LSLaura Willers Souza
Laura Willers Souza
ABAndrei Bieger
Andrei Bieger
WBWyllians Vendramini Borelli
Wyllians Vendramini Borelli
MBMarco Antônio De Bastiani
Marco Antônio De Bastiani
GNGuilherme Bauer Negrini
Guilherme Bauer Negrini
ZLZimmer Neuroimaging Lab
Zimmer Neuroimaging Lab
Background: Multiple studies have linked high cerebrospinal fluid (CSF) cortisol levels, a frequently used biomarker of stress, with the Alzheimer’s disease (AD) pathophysiology. However, the relationship between CSF cortisol levels and AD‐related brain atrophy is not fully understood. Thus, this study sought to determine the association between CSF cortisol levels and neuroimaging biomarkers of brain structure indexed by magnetic resonance imaging (MRI) in patients across the AD spectrum.Methods: Participants with baseline measures of CSF cortisol and structural (high‐resolution T1‐weighted) MRI (n = 300) were selected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The MRI scans were processed with FreeSurfer (v. 7.1.1), and the statistical analyses were performed using R (v. 4.1.1; R Core Team, 2021). We performed a region‐of‐interest (ROI) analysis using a generalized linear model (GLM), to assess the association between CSF cortisol levels and (1) volume of hippocampus, amygdala, subcortical and cortical segmentation, (2) cortical thickness and (3) surface area of cortical structures (Fig. 1). The ROI analysis was corrected by Bonferroni (p < 0.0005).Results: CSF cortisol levels did not correlate with left hippocampal volume (p = 0.2; Fig. 2A) and mean global brain thickness (p = 0.002; Fig. 2C). However, we found a negative correlation with the volume of left fimbria (r = ‐0.20, p = 0.0003; Fig. 2B) and right superior frontal thickness (r = ‐0.21, p = 0.0003; Fig. 2D). In the regression model, only right superior frontal thickness showed significant association with CSF cortisol levels after adjusting for age (corrected R2 = 0.11, p < 0.0001). The other regions and parameters analyzed did not present significant correlations with CSF cortisol levels.Conclusions: This cross‐sectional study found an association between elevated CSF cortisol levels and atrophy of left fimbria and right superior frontal in patients on the AD spectrum. Our findings suggest a particular vulnerability to cortisol in selected regions. To the best of our knowledge, this is the first study to assess the associations between CSF cortisol levels and ROIs from hippocampus and amygdala segmentation. Our results have potential implications for understating AD‐related brain atrophy and developing innovative therapeutic strategies.

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
WBWagner Scheeren Brum
Wagner Scheeren Brum
MBMarco Antônio Bastiani
Marco Antônio Bastiani
JTJoseph Therriault
Joseph Therriault
ABAndrei Bieger
Andrei Bieger
JFJoão Pedro Ferrari‐Souza
João Pedro Ferrari‐Souza
EZEduardo Zimmer
Eduardo Zimmer